Cardiovascular Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cardiovascular Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Adverse Drug Events
New worries tarnishing arthritis drugs
December 7th, 2004
One by one, arthritis drugs that promised to ease pain without causing ulcers are losing their luster. In September, Merck & Co. yanked Vioxx from the market when a trial showed that long-term use of the painkiller nearly doubled the risk of heart attack and stroke. In November, researchers said a preliminary study indicated that Bextra - another painkiller in the same class - also more than doubled the risk of heart attacks and strokes among patients with heart disease. Pfizer, which manufactures Bextra, said researchers made "unsubstantiated conclusions" during their presentation at the annual meeting of the American Heart...
Source: Cardiovascular Business Week (2004-12-07)
|
